JPWO2023167947A5 - - Google Patents
Info
- Publication number
- JPWO2023167947A5 JPWO2023167947A5 JP2024552150A JP2024552150A JPWO2023167947A5 JP WO2023167947 A5 JPWO2023167947 A5 JP WO2023167947A5 JP 2024552150 A JP2024552150 A JP 2024552150A JP 2024552150 A JP2024552150 A JP 2024552150A JP WO2023167947 A5 JPWO2023167947 A5 JP WO2023167947A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide construct
- composition
- nbd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315529P | 2022-03-01 | 2022-03-01 | |
| US63/315,529 | 2022-03-01 | ||
| US202263330120P | 2022-04-12 | 2022-04-12 | |
| US63/330,120 | 2022-04-12 | ||
| US202263353896P | 2022-06-21 | 2022-06-21 | |
| US63/353,896 | 2022-06-21 | ||
| PCT/US2023/014302 WO2023167947A2 (en) | 2022-03-01 | 2023-03-01 | Atp-dependent agonists of immune cells function as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508958A JP2025508958A (ja) | 2025-04-10 |
| JP2025508958A5 JP2025508958A5 (https=) | 2026-03-11 |
| JPWO2023167947A5 true JPWO2023167947A5 (https=) | 2026-03-11 |
Family
ID=87884241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552150A Pending JP2025508958A (ja) | 2022-03-01 | 2023-03-01 | 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12180297B2 (https=) |
| EP (1) | EP4486391A4 (https=) |
| JP (1) | JP2025508958A (https=) |
| KR (1) | KR20240169151A (https=) |
| CN (1) | CN119110731A (https=) |
| AU (1) | AU2023229182A1 (https=) |
| CA (1) | CA3245316A1 (https=) |
| IL (1) | IL315362A (https=) |
| WO (1) | WO2023167947A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508958A (ja) * | 2022-03-01 | 2025-04-10 | クロスリンク セラピューティクス インク． | 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト |
| AU2024336553A1 (en) * | 2023-09-06 | 2026-03-26 | Crosslink Therapeutics Inc. | Atp-dependent agonists of immune cells function as anticancer agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284879B1 (en) | 1998-04-16 | 2001-09-04 | The General Hospital Corporation | Transport associated protein splice variants |
| US6830913B1 (en) | 1999-11-29 | 2004-12-14 | Active Pass Pharmaceuticals, Inc. | ABCB9 transporter and uses thereof |
| EP1217066A1 (en) * | 2000-12-21 | 2002-06-26 | Universiteit Gent | Modulation of ATP-binding cassette transporter activity |
| WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
| EP3678691A4 (en) * | 2017-09-07 | 2021-06-09 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| US11560413B2 (en) * | 2018-02-15 | 2023-01-24 | Uab Research Foundation | Modified cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides with increased stability and uses thereof |
| JP2025508958A (ja) * | 2022-03-01 | 2025-04-10 | クロスリンク セラピューティクス インク． | 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト |
-
2023
- 2023-03-01 JP JP2024552150A patent/JP2025508958A/ja active Pending
- 2023-03-01 WO PCT/US2023/014302 patent/WO2023167947A2/en not_active Ceased
- 2023-03-01 IL IL315362A patent/IL315362A/en unknown
- 2023-03-01 KR KR1020247032672A patent/KR20240169151A/ko active Pending
- 2023-03-01 AU AU2023229182A patent/AU2023229182A1/en active Pending
- 2023-03-01 CN CN202380037296.1A patent/CN119110731A/zh active Pending
- 2023-03-01 EP EP23763905.9A patent/EP4486391A4/en active Pending
- 2023-03-01 CA CA3245316A patent/CA3245316A1/en active Pending
-
2024
- 2024-03-01 US US18/593,028 patent/US12180297B2/en active Active
- 2024-12-20 US US18/989,938 patent/US20250197521A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| IL295878A (en) | Methods for producing cells expressing a chimeric antigen receptor | |
| KR102483755B1 (ko) | 키메라 폴리펩티드 및 그의 용도 | |
| JP6846352B2 (ja) | キメラ抗原受容体 | |
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| JP2021518142A5 (https=) | ||
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| Kermer et al. | Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy | |
| Shirasu et al. | Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes | |
| JP2021531785A5 (https=) | ||
| JP2020516287A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| CA3094996A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| US20250197470A1 (en) | Pooling signaling and costimulatory domains in b7h6 chimeric antigen receptor | |
| JPWO2021071962A5 (https=) | ||
| JP2020525005A5 (https=) | ||
| Abken et al. | Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity | |
| Uherek et al. | Chimeric antigen receptors for the retargeting of cytotoxic effector cells | |
| JPWO2021173985A5 (https=) | ||
| Koch et al. | Recombinant antibodies to arm cytotoxic lymphocytes in cancer immunotherapy | |
| US12180297B2 (en) | ATP-dependent agonists of immune cells function as anticancer agents | |
| JPWO2019165116A5 (https=) | ||
| JPWO2023167947A5 (https=) | ||
| JPWO2021258016A5 (https=) |